can you lose weight with semaglutide Woman shares journey of loss and gain after using How Long Does It Take

A landmark study published in March in The BMJ adds an interesting layer to that picture

In as-treated analyses median follow-up was 1 year [0-2] for both new GLP-1 RA users and new SGLT-2 inhibitor users

Hair loss isnt commonly discussed as a potential side effect of GLP-1 therapy, yet it appeared repeatedly in the database, observed Fat

Age approvals: Wegovy is FDA-approved for weight management in adults and some children ages 12 and older, whereas Zepbound is currently approved only for adults

Mounjaro and Rybelsus both belong to the GLP-1 receptor agonist class of medications, but they differ in how theyre taken, what they treat, and their effectiveness

Patients should be counselled to expect these potential side-effects